UBS analyst Joshua Spector lowered the firm’s price target on Xylem (XYL) to $155 from $168 and keeps a Buy rating on the shares.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XYL:
- Xylem price target lowered to $165 from $170 at Oppenheimer
- Xylem price target lowered to $158 from $175 at Goldman Sachs
- Xylem: Strong Measurement & Control Momentum and Conservative 2026 Outlook Underpin Buy Rating
- Xylem price target lowered to $175 from $178 at Stifel
- Xylem price target lowered to $161 from $178 at Baird